The BRCA1 c. 5096G>A p.Arg1699Gln (R1699Q) intermediate risk variant: Breast and ovarian cancer risk estimation and recommendations for clinical management from the ENIGMA consortium

Research output: Contribution to journalArticle

Abstract

Background We previously showed that the BRCA1 variant c.5096G>A p.Arg1699Gln (R1699Q) was associated with an intermediate risk of breast cancer (BC) and ovarian cancer (OC). This study aimed to assess these cancer risks for R1699Q carriers in a larger cohort, including follow-up of previously studied families, to further define cancer risks and to propose adjusted clinical management of female BRCA1*R1699Q carriers. Methods Data were collected from 129 BRCA1*R1699Q families ascertained internationally by ENIGMA (Evidence-based Network for the Interpretation of Germline Mutant Alleles) consortium members. A modified segregation analysis was used to calculate BC and OC risks. Relative risks were calculated under both monogenic model and major gene plus polygenic model assumptions. Results In this cohort the cumulative risk of BC and OC by age 70 years was 20% and 6%, respectively. The relative risk for developing cancer was higher when using a model that included the effects of both the R1699Q variant and a residual polygenic component compared with monogenic model (for BC 3.67 vs 2.83, and for OC 6.41 vs 5.83). Conclusion Our results confirm that BRCA1*R1699Q confers an intermediate risk for BC and OC. Breast surveillance for female carriers based on mammogram annually from age 40 is advised. Bilateral salpingooophorectomy should be considered based on family history.

Details

Authors
  • Setareh Moghadasi
  • Huong D. Meeks
  • Maaike P G Vreeswijk
  • Linda A.M. Janssen
  • Ylva Paulsson-Karlsson
  • Barbara Wappenschmidt
  • Christoph Engel
  • Andrea Gehrig
  • Norbert Arnold
  • Thomas Van Overeem Hansen
  • Mads Thomassen
  • Uffe Birk Jensen
  • Torben A Kruse
  • Bent Ejlertsen
  • Anne-Marie Gerdes
  • Inge Søkilde Pedersen
  • Sandrine M. Caputo
  • Fergus Couch
  • Emily J. Hallberg
  • Ans M W van den Ouweland
  • J Margriet Collée
  • Erik Teugels
  • Muriel A Adank
  • Rob B van der Luijt
  • Arjen R. Mensenkamp
  • Jan C. Oosterwijk
  • Marinus J. Blok
  • Nicolas Janin
  • Kathleen B M Claes
  • Kathy Tucker
  • Valeria Viassolo
  • Amanda Ewart Toland
  • Diana E. Eccles
  • Peter Devilee
  • Christie J. Van Asperen
  • Amanda B Spurdle
  • David E Goldgar
  • Encarna Gómez García
Organisations
External organisations
  • Leiden University Medical Centre
  • Uppsala University
  • University Hospital of Cologne
  • Leipzig University
  • Julius Maximilian University of Würzburg
  • University Medical Center Schleswig-Holstein Campus Kiel
  • Odense University Hospital
  • Aarhus University Hospital
  • University of Copenhagen
  • Aalborg University
  • Curie Institute, Paris
  • Mayo Clinic Minnesota
  • Erasmus University Medical Center
  • Universitair Ziekenhuis Brussel
  • Amsterdam UMC - Vrije Universiteit Amsterdam
  • University Medical Center Utrecht
  • University Medical Center Groningen
  • Maastricht University
  • Saint-Luc University Hospital
  • Ghent University Hospital
  • Prince of Wales Hospital
  • Geneva University Hospital
  • Ohio State University
  • University of Southampton
  • QIMR Berghofer Medical Research Institute
  • University of Utah
Research areas and keywords

Subject classification (UKÄ) – MANDATORY

  • Cancer and Oncology
Original languageEnglish
Pages (from-to)15-20
JournalJournal of Medical Genetics
Volume55
Issue number1
Early online date2017 May 10
Publication statusPublished - 2018
Publication categoryResearch
Peer-reviewedYes